TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00787787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study: NCT00177515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video doctor, computer module
Description: computerized counseling about emergency contraception and peri-conception folate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video doctor, computer module
Description: computerized counseling about emergency contraception and peri-conception folate
Study: NCT04151459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study: NCT03748524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
Study: NCT04187833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg intravenously every 4 weeks (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1mg orally daily
Study: NCT02872259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB324+pembrolizumab
Description: Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB324+dabrafenib and trametinib
Description: Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: Monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabrafenib and trametinib
Description: Combination
Study: NCT04148495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of acetaminophen IV
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen IV
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g
Study: NCT03365245

Intervention type: DEVICE
Group type: OTHER
Intervention: Microperimetry
Description: Microperimetry is performed at three different days

Intervention type: DEVICE
Group type: OTHER
Intervention: automated visual field
Description: Automated visual field ist performed at three different days
Study: NCT02736448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral low dose of capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PRRT
Description: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PRRT
Description: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
Study: NCT03979404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
Study: NCT03007875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT01055327

Intervention type: DRUG
Intervention: Lamotrigine monotherapy
Description: Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).

Intervention type: DRUG
Intervention: No anti-epileptic drug exposure
Description: No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).

Intervention type: DRUG
Intervention: Non lamotrigine anti-epileptic drug monotherapy
Description: Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
Study: NCT05042297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention
Description: Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention
Description: Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
Study: NCT02373072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: 300mg TID, Capsules. Optional in both Cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: 300mg TID, Capsules. Optional in both Cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects completing all three treatment periods will be receiving placebo once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects completing all three treatment periods will be receiving placebo once.
Study: NCT02756897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03375684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
Study: NCT02736448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-LAR
Description: long acting octreotide or lanreotide
Study: NCT04308135

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory (BDI)(Arabic version)
Description: Clinical Tool for depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory (BDI)(Arabic version)
Description: Clinical Tool for depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory (BDI)(Arabic version)
Description: Clinical Tool for depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Tools for Urinary symptoms:
Description: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Tools for Urinary symptoms:
Description: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Tools for Urinary symptoms:
Description: the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)

Intervention type: DIAGNOSTIC_TEST
Intervention: Freezing of gait questionnaire
Description: Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Freezing of gait questionnaire
Description: Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test.
Study: NCT04308135

Intervention type: DIAGNOSTIC_TEST
Intervention: Freezing of gait questionnaire
Description: Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test.

Intervention type: DIAGNOSTIC_TEST
Intervention: non-motor symptoms scales (NMSS).
Description: Clinical Tool for assessment of non-motor symptoms of PD

Intervention type: DIAGNOSTIC_TEST
Intervention: non-motor symptoms scales (NMSS).
Description: Clinical Tool for assessment of non-motor symptoms of PD
Study: NCT04249843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: administered orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3245
Description: administered orally (PO)
Study: NCT03854227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 dose escalation
Description: PF-06939999 orally at escalating doses on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 monotherapy
Description: PF-06939999 at the recommended Phase 2 dose orally on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 monotherapy
Description: PF-06939999 at the recommended Phase 2 dose orally on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 monotherapy
Description: PF-06939999 at the recommended Phase 2 dose orally on a continuous basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 in combination with docetaxel
Description: PF-06939999 orally on a continuous basis in combination with docetaxel
Study: NCT00870584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Study: NCT01948856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J022X ST
Description: Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Study: NCT04125953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andullation
Description: Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Andullation
Study: NCT03854227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06939999 in combination with docetaxel
Description: PF-06939999 orally on a continuous basis in combination with docetaxel
Study: NCT02559492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: INCB050465 tablets will be administered orally once daily.
Study: NCT03131908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
Study: NCT03103893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: topical formulation
Study: NCT04210271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy self-testing condition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control self-screening condition
Study: NCT01189383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL15-DC Vaccine
Description: Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
Study: NCT02834949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance-Free Activity Session (SFAS)
Description: The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Session
Description: The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
Study: NCT04234737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Hypnotherapy
Study: NCT05112796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class I extractions sites received immediate implants using the Vestibular Socket Therapy
Description: A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I extractions sites received immediate implants using the Partial Extraction Therapy
Description: the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
Study: NCT03012581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Treatment
Study: NCT03601637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM
Description: Fixed Dose Combination (FDC) granules (LUM/IVA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM
Description: Fixed Dose Combination (FDC) granules (LUM/IVA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: FDC granules (LUM/IVA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: FDC granules (LUM/IVA).
Study: NCT03675828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
Study: NCT01353469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human/Insuman Comb 25 (HR1799)
Description: Pharmaceutical form:Suspension~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin human/Novolin® 30R
Description: Pharmaceutical form:Suspension~Route of administration: Subcutaneous
Study: NCT04452656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae block
Description: An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12.
Study: NCT02332148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3VM1001
Description: 3VM1001 topical cream for treatment of osteoarthritis of the knee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3VM1001
Description: Topical cream placebo for 3VM1001; cream without 3VM1001
Study: NCT03962023

Intervention type: OTHER
Intervention: Echocardiography and MRI
Description: Analysis of echocardiography and MRI parameters
Study: NCT02916290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu
Study: NCT01800942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and Placebo
Description: A single oral dose of 2g of Azithromycin will be given to the women in labour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin and Placebo
Description: A single oral dose of 2g of Azithromycin will be given to the women in labour
Study: NCT03257189

Intervention type: DEVICE
Group type: OTHER
Intervention: Physiological signal monitor
Description: Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.

Intervention type: DEVICE
Group type: OTHER
Intervention: Heart rate and heart rate variability comparison device
Description: FDA cleared reference device that monitors heart rate and heart rate variability in subjects

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiration rate comparison device
Description: FDA cleared reference device that monitors respiration rate in subjects

Intervention type: OTHER
Group type: OTHER
Intervention: Activity classification
Description: Visual annotation of subject posture and other activities used for reference